Ginkgo Bioworks Holdings, Inc.
DNANYSEHealthcare● Active
$8.09
$-0.13(-1.58%)
Market Cap$528475173
P/E Ratio—
52W High$17.58
52W Low$5.37
Ginkgo Bioworks Holdings, Inc. (DNA) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DNA · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.31B) | ($0.55B) | ($0.89B) | ($2.11B) | ($1.84B) |
| Depreciation & Amort. | $0.06B | $0.06B | $0.07B | $0.04B | $0.03B |
| Stock-Based Comp. | $0.08B | $0.11B | $0.23B | $1.93B | $1.61B |
| Change in Working Capital | ($0.04B) | ($0.09B) | $0.03B | ($0.04B) | ($0.06B) |
| Net Cash from Operations | ($0.17B) | ($0.32B) | ($0.30B) | ($0.25B) | ($0.25B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.01B) | ($0.06B) | ($0.04B) | ($0.05B) | ($0.06B) |
| Purchases of Investments | ($0.42B) | $0.00B | $0.00B | ($0.00B) | ($0.01B) |
| Sales of Investments | $0.19B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Investing | ($0.24B) | ($0.06B) | ($0.08B) | ($0.07B) | ($0.07B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | ($0.00B) | $0.00B | ($0.02B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Cash from Financing | $0.02B | ($0.00B) | ($0.00B) | $0.10B | $1.53B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.18B) | ($0.38B) | ($0.34B) | ($0.30B) | ($0.31B) |
| FCF Margin %(computed) | -105.04% | -168.31% | -133.74% | -63.74% | -98.89% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Ginkgo Bioworks Holdings, Inc. data
About Ginkgo Bioworks Holdings, Inc. (DNA) Cash Flow Statement
Ginkgo Bioworks Holdings, Inc. generated operating cash flow of ($0.17B) and free cash flow of ($0.18B) for 2025 — a FCF margin of -105.04%. Capital expenditure was ($0.01B).
Frequently asked questions
DNA · 4 questionsGinkgo Bioworks Holdings, Inc. generated free cash flow of ($0.18B) for 2025, up 53.2% year-over-year.
DNA free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10